Market capitalization | $1.44b |
Enterprise Value | $479.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.94 |
P/S ratio (TTM) P/S ratio | 5.82 |
P/B ratio (TTM) P/B ratio | 2.26 |
Revenue growth (TTM) Revenue growth | 103.73% |
Revenue (TTM) Revenue | $247.00m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Arcus Biosciences forecast:
10 Analysts have issued a Arcus Biosciences forecast:
Jun '24 |
+/-
%
|
||
Revenue | 247 247 |
104%
104%
|
|
Gross Profit | 234 234 |
120%
120%
|
|
EBITDA | -260 -260 |
13%
13%
|
EBIT (Operating Income) EBIT | -273 -273 |
13%
13%
|
Net Profit | -249 -249 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Head office | United States |
CEO | Terry Rosen |
Employees | 577 |
Founded | 2015 |
Website | www.arcusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.